Literature DB >> 8841325

Stroke severity in atrial fibrillation. The Framingham Study.

H J Lin1, P A Wolf, M Kelly-Hayes, A S Beiser, C S Kase, E J Benjamin, R B D'Agostino.   

Abstract

BACKGROUND AND
PURPOSE: Stroke occurring with atrial fibrillation (AF) is more likely to be fatal or more severe than non-AF stroke based on clinical series, but data from prospective epidemiological studies are sparse and inconsistent.
METHODS: Over 40-year follow-up of the original 5070 Framingham cohort, 501 initial ischemic strokes, including 103 with AF, were analyzed. Stroke severity was rated as none, mild, moderate, severe, or fatal. Since 1981, functional status indicated by the Barthel index has been evaluated acutely and at 3, 6, and 12 months. Severity and functional status of AF strokes were compared with non-AF strokes using chi 2 test and Student's t test. Thirty-day mortality was assessed by logistic regression analyses.
RESULTS: AF was associated with increased stroke severity (P = .048). Thirty-day mortality was greater in AF strokes than in non-AF strokes (25% versus 14%). The multivariate-adjusted odds ratio for 30-day mortality for AF subjects was 1.84 (95% confidence interval, 1.04 to 3.27). Since 1981, follow-up was available for 150 initial ischemic strokes, including 30 with AF. Compared with the non-AF group, the AF group had poorer survival and more recurrences during 1 year of follow-up. The AF subjects had lower mean Barthel index scores acutely (29.6 versus 58.6, P < .001) and at 3 months (P = .005), 6 months (P = .003), and 12 months (P = .130) after stroke among survivors.
CONCLUSIONS: Ischemic stroke associated with AF was nearly twice as likely to be fatal as non-AF stroke. Recurrence was more frequent, and functional deficits were more likely to be severe among survivors. Since stroke is usually the initial manifestation of embolism in AF, prevention is critical to reducing disability and mortality.

Entities:  

Mesh:

Year:  1996        PMID: 8841325     DOI: 10.1161/01.str.27.10.1760

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  307 in total

Review 1.  Report of the NASPE/NHLBI Round Table on Future Research Directions in Atrial Fibrillation. North American Society of Pacing and Electrophysiology.

Authors:  S Saskena; M J Domanski; E J Benjamin; A J Camm; M D Ezekowitz; B J Gersh; J Jalife; G V Naccarelli; R E Vlietstra; D G Wyse
Journal:  J Interv Card Electrophysiol       Date:  2001-09       Impact factor: 1.900

Review 2.  Very low-intensity antithrombotic therapy in atrial fibrillation.

Authors:  B G Koefoed; P Petersen
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

3.  [Persistent left atrial thrombus in atrial fibrillation under oral anticoagulation].

Authors:  B Leithäuser; F Kasch; T Broemel; J-W Park
Journal:  Herz       Date:  2010-12       Impact factor: 1.443

4.  Etiologic stroke subtypes: updated definition and efficient workup strategies.

Authors:  Prachi Mehndiratta; Sherita Chapman Smith; Bradford B Worrall
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-01

5.  [Epidemiology, clinical picture and management of atrial fibrillation].

Authors:  J Röther
Journal:  Nervenarzt       Date:  2011-02       Impact factor: 1.214

6.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2011-12-15       Impact factor: 29.690

Review 7.  Promise of factor Xa inhibition in atrial fibrillation.

Authors:  Sana M Al-Khatib; John H Alexander; Renato D Lopes; Kenneth W Mahaffey; Manesh R Patel; Christopher B Granger
Journal:  Curr Cardiol Rep       Date:  2012-02       Impact factor: 2.931

8.  Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage.

Authors:  Aditi Shendre; Gaurav M Parmar; Chrisly Dillon; Timothy Mark Beasley; Nita A Limdi
Journal:  Pharmacotherapy       Date:  2018-02-27       Impact factor: 4.705

9.  Cardiac embolism after implantable cardiac defibrillator shock in non-anticoagulated atrial fibrillation: The role of left atrial appendage occlusion.

Authors:  Xavier Freixa; Rut Andrea; Victoria Martín-Yuste; Diego Fernández-Rodríguez; Salvatore Brugaletta; Mónica Masotti; Manel Sabaté
Journal:  World J Cardiol       Date:  2014-04-26

10.  Incidence of Thromboembolic Complications Within 30 Days of Electrical Cardioversion Performed Within 48 Hours of Atrial Fibrillation Onset.

Authors:  Aatish Garg; Monica Khunger; Sinziana Seicean; Mina K Chung; Patrick J Tchou
Journal:  JACC Clin Electrophysiol       Date:  2016-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.